Membranes Seminar

Abstract

Nearly 25% of adults are currently living with either pre-diabetes or diabetes mellitus, which can ultimately cause life-threatening conditions such as diabetic kidney disease (DKD), a form of chronic kidney disease (CKD), and cardiovascular disease. Approximately 50% of patients on dialysis have DKD; and dialysis, in and of itself, is associated with a significant risk of cardiovascular disease and mortality. One of the consequences of a decline in kidney function is deranged mineral (phosphate/calcium) homeostasis. The resulting hyperphosphatemia significantly contributes to vascular calcifications and elevated blood fibroblast growth factor 23 (FGF23, a bone-derived phosphaturic peptide) levels. The latter has been shown to directly cause ventricular hypertrophy/heart failure in DKD. Treating hyperphosphatemia in DKD remains to be a significant challenge. The current treatment options are limited to dietary phosphate (Pi) restriction, oral Pi binders, and niacin/nicotinamide; however, all have been proven to be insufficient. Of note, the development of sodium/glucose co-transporter 2 (SGLT2) inhibitors, which have become a new mainstay in the treatment of diabetes mellitus, brought a significant change to the treatment of diabetes because, for the 1st time in 40 years, a novel drug slowed the progression of kidney function decline in type 2 diabetes mellitus (T2DM) patients with CKD. After attending this seminar, the attendees should be able to: (i) understand the physiology of renal glucose transport, (ii) understand the value of sodium-glucose cotransport inhibitors in the treatment of CKD, and (iii) comprehend novel treatment approaches for deranged Pi homeostasis and associated hormonal disturbances.

Join by zoom meeting: https://aarhusuniversity.zoom.us/j/62276872934

Host: Prof. Robert Fenton

Søren Brandt Poulsen
Administrative Research Theme Coordinator
MEMBRANES